Consolidated Balance Sheets - USD ($)	Dec. 31, 2015	Dec. 31, 2014
Current assets:
Cash and cash equivalents	$ 22,604,481	$ 23,222,296
Supplies for clinical trials	1,158,632	0
Other assets	797,425	1,219,873
Total current assets	24,560,538	24,442,169
Property and equipment, net	180,922	47,365
Supplies for clinical trials	1,115,657	227,097
Deposits	4,176,280	356,367
Deferred financing costs	(48,977)	(105,563)
Total assets	30,082,374	25,178,561
Current liabilities:
Accounts payable	1,161,258	322,002
Accrued compensation and benefits	790,487	334,527
Accrued liabilities	317,653	632,670
Total current liabilities	2,269,398	1,289,199
CIRM liability	4,133,905	0
Warrant Liability	1,958,775	597,719
Total liabilities	$ 8,362,078	$ 1,886,918
Commitments and contingencies (Note 5)
Shareholders’ equity:
Common stock, $0.0001 par value; 249,000,000 and 149,000,000 shares authorized as of December 31, 2015 and 2014 respectively; 90,310,149 and 63,604,823 shares issued and outstanding as of December 31, 2015 and December 31, 2014, respectively	$ 9,031	$ 6,360
Additional paid-in capital	95,849,005	84,632,209
Accumulated deficit	(74,137,740)	(61,346,926)
Total shareholders’ equity	21,720,296	23,291,643
Total liabilities and shareholders’ equity	$ 30,082,374	$ 25,178,561